The upgraded test includes new gene targets for methicillin resistance, and provides room-temperature storage and validation on multiple swab types.
The test is the 20th US-IVD molecular diagnostic on the GeneXpert menu — Cepheid also recently announced that it has now placed its 10,000 systems globally.
The firm attributed the growth to record reagent revenues and GeneXpert system placements.
Executives from several life science research tool and diagnostic firms provided conference attendees with updates on their businesses.
Cepheid will create Xpert cartridge tests to detect S. aureus and P. aeuginosa, to be used in clinical trials for biologics intended to prevent pneumonia.
The firm reported preliminary financial results in line with previous guidance and the average Wall Street estimate.
The firm signed a memorandum of understanding with the agency and is expected to detail the terms of the cooperation in a subsequent collaborative agreement.
The agreement extends Cepheid's reach beyond the hospital lab environment into the moderately complex lab space.
The test is the first of several planned CLIA-waived assays from Cepheid, and the first point-of-care test on the market to differentiate flu from RSV.
The partners are broadening their collaboration to bring point-of-care TB diagnostics to all levels of the health system in low- and middle-income countries.
An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.
An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.
In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.
Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.